A new era of computational biology.
Our Deep integrated Genomic Analysis Platform DiGAP™ is a bioinformatic "variant hunter" that enables the most comprehensive profiling of the genetic drivers of motor neuron degeneration (MND) or amyotrophic lateral sclerosis (ALS). This platform enables the discovery and development of potential therapeutics that we then test in human cell model systems.
DiGAP also analyzes how these genetic drivers interact to drive specific cellular neurodegenerative processes, which enables classification of patient subgroups, and targeted treatment options.
By looking deeply, at the molecular level, we can analyse various interactions and then attempt to map and validate these against cellular level functions. At the same time, we can compare and contrast both sets of findings against larger datasets. Our unique platform collates genomic data from many entities to give us both a micro and macro picture.
We are also using DiGAP™ pipelines and algorithms to gain more insight into each patient’s genomic map. The first application of this is the DiGAP™ Pathways test for ALS/MND.
Want to know more?
We kindly invite you to participate in a survey to share your thoughts and perspectives. Your responses will help us understand how our platform can best support your research and development efforts in neurodegenerative diseases.
The survey should take approximately 10 minutes to complete.